Immuneering Corporation
IMRX
$3.95
-$0.08-1.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -54.44M | -56.02M | -62.50M | -62.13M | -61.77M |
| Total Depreciation and Amortization | 349.90K | 353.80K | 364.00K | 374.10K | 380.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.05M | 6.50M | 6.68M | 6.83M | 6.95M |
| Change in Net Operating Assets | -1.66M | 3.82M | 5.43M | 3.42M | 856.20K |
| Cash from Operations | -49.70M | -45.34M | -50.01M | -51.51M | -53.59M |
| Capital Expenditure | -213.20K | -142.20K | -27.70K | -25.70K | -56.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -151.59M | -88.60M | 5.50M | 89.80K | 5.09M |
| Cash from Investing | -151.80M | -88.74M | 5.47M | 64.20K | 5.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 216.88M | 230.51M | 230.18M | 18.28M | 18.28M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.93M | -3.93M | -3.28M | -205.00K | -141.00K |
| Cash from Financing | 212.95M | 226.58M | 226.90M | 18.07M | 18.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.46M | 92.50M | 182.36M | -33.37M | -30.42M |